Mark Ragosa - 01 May 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 May 2025, 16:50:42 UTC
Prior SEC filing
01 May 2025
Next SEC filing
05 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Filing notes and source

Key filing fact

Mark Ragosa filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 05 May 2025.

Key facts

  • This page summarizes Mark Ragosa's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 05 May 2025, 16:50.

Change

  • Previous filing in this sequence was filed on 01 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835458 Primary reporting owner

Ragosa Mark

Relationship
CHIEF FINANCIAL OFFICER
Address
23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Signature date
05 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+4,558
Change %
Price
$0.000000
Shares after
4,558
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
4,558
Exercise price
Footnotes
F1, F2, F3
KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+4,786
Change %
+5318%
Price
$0.000000
Shares after
4,876
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
4,786
Exercise price
Footnotes
F1, F2, F4
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+7,368
Change %
Price
$0.000000
Shares after
7,368
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
7,368
Exercise price
$27.74
Footnotes
F2, F5
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+7,606
Change %
Price
$0.000000
Shares after
7,606
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
7,606
Exercise price
$27.74
Footnotes
F2, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance

Footnote F2

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

Footnote F3

The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F4

The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F5

The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

Footnote F6

The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .